Phase 2 Pulmonary Hypertension Trial, Recruiting NCT06038630 Sponsor: Bastiaan Driehuys Condition: Pulmonary Hypertension
Back to Pulmonary Hypertension

Phase 2 Pulmonary Hypertension Trial, Recruiting

NCT06038630
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

Healthy volunteers may be eligible if they:

  • Are over 18 years old and are being seen as an outpatient
  • Are willing and able to give informed consent and follow the study schedule
  • Have no diagnosed lung conditions
  • Have not smoked in the past 5 years
  • Have a smoking history of 5 pack-years or less (if any history at all)
  • Have not regularly used inhaled products (such as inhalers or vapes) more than once a week for more than one year

People receiving a blood transfusion or phlebotomy (blood removal) may be eligible if they:

  • Are over 18 years old (inpatient or outpatient, any gender)
  • Are willing and able to give informed consent and follow the study schedule
  • Are scheduled to receive a red blood cell transfusion for anemia, OR are scheduled for therapeutic phlebotomy (a procedure where blood is removed to treat a condition where the body makes too many red blood cells), OR are a healthy volunteer donating blood who also meets the healthy volunteer criteria listed above

People receiving oxygen treatment may be eligible if they:

  • Are over 18 years old (inpatient or outpatient, any gender)
  • Are willing and able to give informed consent and follow the study schedule
  • Have been diagnosed with Interstitial Lung Disease (a group of lung conditions that cause scarring) by a lung specialist, OR have been referred to a specialist for unexplained shortness of breath, OR have been diagnosed with Chronic Thromboembolic Pulmonary Hypertension (CTEPH — a condition involving high blood pressure in the lungs caused by old blood clots) meeting specific pressure measurements confirmed by a heart procedure, are scheduled for a specific type of lung surgery, and are willing to return for optional follow-up scans 3–6 months later, OR are a healthy volunteer who meets the healthy volunteer criteria listed above

People with a pulmonary embolism (blood clot in the lungs) may be eligible if they:

  • Are over 18 years old (inpatient or outpatient, any gender)
  • Are willing and able to give informed consent and follow the study schedule
  • Have had an acute (sudden/recent) pulmonary embolism and are 24–48 hours past hospital admission, and are willing to return after 3–6 months of blood-thinning treatment, OR have been diagnosed with CTEPH meeting specific pressure measurements confirmed by a heart procedure, are scheduled for a specific type of lung surgery, and are willing to return for optional follow-up scans 3–6 months later

Who may not be able to join:

  • People for whom an MRI scan is not safe based on a standard MRI screening questionnaire
  • People who are pregnant or breastfeeding
  • People whose blood oxygen level is below 90% even with the maximum oxygen that can be delivered through a nasal tube
  • People who have had a respiratory illness caused by a bacterial or viral infection within the past 30 days
  • People with a known history of abnormal heart rhythms originating in the lower chambers of the heart
  • People who have had a cardiac arrest within the past year
  • People whose body size does not fit the specialised MRI vest used in the study
  • People who cannot hold their breath for 10 seconds
  • People who are unlikely to be able to follow instructions during the scan
  • People with medical or psychological conditions that, in the opinion of the study team, could put them at undue risk or prevent them from following the study requirements

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Joseph Mammarappallil, MD, Duke University

Phone: 919-684-7786

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Bastiaan Driehuys
Registry
ClinicalTrials.gov
Start date
12 January 2024
Est. completion
30 June 2028

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Change in RBC to Membrane Ratio Pre and Post Transfusion or Apheresis; Change in RBC (red blood cell) Chemical Shift After Oxygen Administration; Change in RBC Oscillation Amplitude Post Therapy

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov